Last reviewed · How we verify

Placebo of Reconyl

Dexa Medica Group · Phase 3 active Small molecule

Placebo of Reconyl is a Small molecule drug developed by Dexa Medica Group. It is currently in Phase 3 development for Treatment of symptoms in clinical trials.

This drug is a placebo, meaning it has no active therapeutic effect.

This drug is a placebo, meaning it has no active therapeutic effect. Used for Treatment of symptoms in clinical trials.

At a glance

Generic namePlacebo of Reconyl
SponsorDexa Medica Group
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of Reconyl

What is Placebo of Reconyl?

Placebo of Reconyl is a Small molecule drug developed by Dexa Medica Group, indicated for Treatment of symptoms in clinical trials.

How does Placebo of Reconyl work?

This drug is a placebo, meaning it has no active therapeutic effect.

What is Placebo of Reconyl used for?

Placebo of Reconyl is indicated for Treatment of symptoms in clinical trials.

Who makes Placebo of Reconyl?

Placebo of Reconyl is developed by Dexa Medica Group (see full Dexa Medica Group pipeline at /company/dexa-medica-group).

What development phase is Placebo of Reconyl in?

Placebo of Reconyl is in Phase 3.

Related